These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

428 related articles for article (PubMed ID: 10418981)

  • 1. EM-652 (SCH 57068), a third generation SERM acting as pure antiestrogen in the mammary gland and endometrium.
    Labrie F; Labrie C; Bélanger A; Simard J; Gauthier S; Luu-The V; Mérand Y; Giguere V; Candas B; Luo S; Martel C; Singh SM; Fournier M; Coquet A; Richard V; Charbonneau R; Charpenet G; Tremblay A; Tremblay G; Cusan L; Veilleux R
    J Steroid Biochem Mol Biol; 1999; 69(1-6):51-84. PubMed ID: 10418981
    [TBL] [Abstract][Full Text] [Related]  

  • 2. EM-652 (SCH57068), a pure SERM having complete antiestrogenic activity in the mammary gland and endometrium.
    Labrie F; Labrie C; Bélanger A; Simard J; Giguère V; Tremblay A; Tremblay G
    J Steroid Biochem Mol Biol; 2001 Dec; 79(1-5):213-25. PubMed ID: 11850228
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of the effects of EM-652 (SCH57068), tamoxifen, toremifene, droloxifene, idoxifene, GW-5638 and raloxifene on the growth of human ZR-75-1 breast tumors in nude mice.
    Gutman M; Couillard S; Roy J; Labrie F; Candas B; Labrie C
    Int J Cancer; 2002 May; 99(2):273-8. PubMed ID: 11979444
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Blockade of the stimulatory effect of estrogens, OH-tamoxifen, OH-toremifene, droloxifene, and raloxifene on alkaline phosphatase activity by the antiestrogen EM-800 in human endometrial adenocarcinoma Ishikawa cells.
    Simard J; Sanchez R; Poirier D; Gauthier S; Singh SM; Merand Y; Belanger A; Labrie C; Labrie F
    Cancer Res; 1997 Aug; 57(16):3494-7. PubMed ID: 9270018
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of the effects of the novel non-steroidal antiestrogen EM-800 on basal and estrogen-induced proliferation of T-47D, ZR-75-1 and MCF-7 human breast cancer cells in vitro.
    Simard J; Labrie C; Bélanger A; Gauthier S; Singh SM; Mérand Y; Labrie F
    Int J Cancer; 1997 Sep; 73(1):104-12. PubMed ID: 9334816
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibitory effects of medroxyprogesterone acetate (MPA) and the pure antiestrogen EM-219 on estrone (E1)-stimulated growth of dimethylbenz(a)anthracene (DMBA)-induced mammary carcinoma in the rat.
    Li S; Lévesque C; Geng CS; Yan X; Labrie F
    Breast Cancer Res Treat; 1995 May; 34(2):147-59. PubMed ID: 7647332
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antiestrogenic properties of keoxifene, trans-4-hydroxytamoxifen, and ICI 164384, a new steroidal antiestrogen, in ZR-75-1 human breast cancer cells.
    Poulin R; Merand Y; Poirier D; Levesque C; Dufour JM; Labrie F
    Breast Cancer Res Treat; 1989 Oct; 14(1):65-76. PubMed ID: 2605344
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Binding characteristics of novel nonsteroidal antiestrogens to the rat uterine estrogen receptors.
    Martel C; Provencher L; Li X; St Pierre A; Leblanc G; Gauthier S; Mérand Y; Labrie F
    J Steroid Biochem Mol Biol; 1998 Feb; 64(3-4):199-205. PubMed ID: 9605415
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Human estrogen receptor ligand activity inversion mutants: receptors that interpret antiestrogens as estrogens and estrogens as antiestrogens and discriminate among different antiestrogens.
    Montano MM; Ekena K; Krueger KD; Keller AL; Katzenellenbogen BS
    Mol Endocrinol; 1996 Mar; 10(3):230-42. PubMed ID: 8833652
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Estrogen and aryl hydrocarbon responsiveness of ECC-1 endometrial cancer cells.
    Castro-Rivera E; Wormke M; Safe S
    Mol Cell Endocrinol; 1999 Apr; 150(1-2):11-21. PubMed ID: 10411295
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of a new clinically relevant antiestrogen (GW5638) related to tamoxifen on breast and endometrial cancer growth in vivo.
    Dardes RC; O'Regan RM; Gajdos C; Robinson SP; Bentrem D; De Los Reyes A; Jordan VC
    Clin Cancer Res; 2002 Jun; 8(6):1995-2001. PubMed ID: 12060645
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Allosteric silencing of activating function 1 in the 4-hydroxytamoxifen estrogen receptor complex is induced by substituting glycine for aspartate at amino acid 351.
    MacGregor Schafer J; Liu H; Bentrem DJ; Zapf JW; Jordan VC
    Cancer Res; 2000 Sep; 60(18):5097-105. PubMed ID: 11016635
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The interaction of raloxifene and the active metabolite of the antiestrogen EM-800 (SC 5705) with the human estrogen receptor.
    Schafer JI; Liu H; Tonetti DA; Jordan VC
    Cancer Res; 1999 Sep; 59(17):4308-13. PubMed ID: 10485477
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of the effects of a pure steroidal antiestrogen with those of tamoxifen in a model of human breast cancer.
    Osborne CK; Coronado-Heinsohn EB; Hilsenbeck SG; McCue BL; Wakeling AE; McClelland RA; Manning DL; Nicholson RI
    J Natl Cancer Inst; 1995 May; 87(10):746-50. PubMed ID: 7563152
    [TBL] [Abstract][Full Text] [Related]  

  • 15. EM-800, a novel antiestrogen, acts as a pure antagonist of the transcriptional functions of estrogen receptors alpha and beta.
    Tremblay A; Tremblay GB; Labrie C; Labrie F; Giguère V
    Endocrinology; 1998 Jan; 139(1):111-8. PubMed ID: 9421405
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of human estrogen receptor using an efficient adenoviral gene delivery system is able to restore hormone-dependent features to estrogen receptor-negative breast carcinoma cells.
    Lazennec G; Katzenellenbogen BS
    Mol Cell Endocrinol; 1999 Mar; 149(1-2):93-105. PubMed ID: 10375022
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 17 beta-estradiol- and 4-hydroxytamoxifen-induced transactivation in breast, endometrial and liver cancer cells is dependent on ER-subtype, cell and promoter context.
    Castro-Rivera E; Safe S
    J Steroid Biochem Mol Biol; 2003 Jan; 84(1):23-31. PubMed ID: 12648521
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular mechanism of action at estrogen receptor alpha of a new clinically relevant antiestrogen (GW7604) related to tamoxifen.
    Bentrem D; Dardes R; Liu H; MacGregor-Schafer J; Zapf J; Jordan V
    Endocrinology; 2001 Feb; 142(2):838-46. PubMed ID: 11159857
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Estrogen inhibits the growth of estrogen receptor-negative, but not estrogen receptor-positive, human mammary epithelial cells expressing a recombinant estrogen receptor.
    Zajchowski DA; Sager R; Webster L
    Cancer Res; 1993 Oct; 53(20):5004-11. PubMed ID: 8402691
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Basic guide to the mechanisms of antiestrogen action.
    MacGregor JI; Jordan VC
    Pharmacol Rev; 1998 Jun; 50(2):151-96. PubMed ID: 9647865
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.